세계의 올리고뉴클레오티드 합성 시장 : 제품 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Oligonucleotide Synthesis Market was valued at USD 10.29 billion in 2023, expected to reach USD 12.24 billion in 2024, and is projected to grow at a CAGR of 20.24%, to USD 37.41 billion by 2030.

Oligonucleotide synthesis involves the chemical synthesis of short sequences of nucleotides, which are the building blocks of DNA and RNA. This process is essential for various research and therapeutic applications, including drug development, genetic testing, and molecular diagnostics. The demand for synthesized oligonucleotides is propelled by the growing emphasis on personalized medicine, advances in biotechnology, and the increasing prevalence of genetic disorders. Key end-users include pharmaceuticals, biotechnology companies, academic institutes, and research organizations. The market is buoyed by the urgent need for innovative genetic therapies and advancements in fields like genomics and proteomics. Growth in this sector is driven by factors such as technological advancements in synthesis techniques, the expansion of research activities, and increased funding for genomics projects. However, challenges such as high costs of synthesis, complex regulatory landscapes, and technical difficulties in large-scale production pose limitations. Opportunities abound in developing cost-effective, high-throughput synthesis platforms and enhancing the accuracy and efficiency of oligonucleotide drugs. Nanoscale oligonucleotide synthesis and integration with AI for predictive analytics present significant innovation opportunities. Despite intense competition, strategic partnerships and collaborations are indispensable for market penetration and expansion. Additionally, focusing on sustainable manufacturing technologies and integrating eco-friendly approaches could yield competitive advantages. Market players should also keep an eye on the evolving regulatory environment to mitigate compliance-related risks. Potential growth areas include novel therapeutic areas such as rare diseases and infectious diseases. Encouraging open innovation and fostering collaborations with academic and research institutions can spur novel discoveries and applications, helping companies stay at the forefront. In summary, while the oligonucleotide synthesis market presents a landscape ripe with opportunities, stakeholders must navigate the accompanying challenges adeptly to harness its full potential for sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oligonucleotide Synthesis Market

The Oligonucleotide Synthesis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases and growing focus on drug discovery
  • Rising usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
  • Significant investments in pharmaceutical and biotechnology research
• Market Restraints
  • High cost of oligonucleotides production
• Market Opportunities
  • Improvements and advances in oligonucleotide synthesis
  • Strategic alliances for increasing production of oligonucleotides
• Market Challenges
  • Complications associated with large scale oligonucleotide synthesis

Porter's Five Forces: A Strategic Tool for Navigating the Oligonucleotide Synthesis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oligonucleotide Synthesis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oligonucleotide Synthesis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oligonucleotide Synthesis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oligonucleotide Synthesis Market

A detailed market share analysis in the Oligonucleotide Synthesis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oligonucleotide Synthesis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oligonucleotide Synthesis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oligonucleotide Synthesis Market

A strategic analysis of the Oligonucleotide Synthesis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oligonucleotide Synthesis Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, ATDBio Ltd., Bio-synthesis Inc., Biocomma Ltd., Biolegio B.V., Biolytic Lab Performance Inc., Bioserve India by Reprocell Group, Bon Opus Biosciences, LLC, Creative Biogene, Cusabio Technology LLC, Danaher Corporation, Eurofins Genomics LLC, Eurogentec S.A. by Kaneka Corporation, GE Healthcare Inc., Generi Biotech, Genscript Corporation, Hongene Biotech Corp., LGC Genomics Limited, Merck KGaA, Microsynth AG, Nitto Denko Avecia Inc., Novartis AG, PerkinElmer, Inc., Synbio Technologies, TAG Copenhagen A/S, TCI Chemicals (India) Pvt. Ltd., Thermo Fisher Scientific Inc., and TriLink BioTechnologies, Inc..

Market Segmentation & Coverage

This research report categorizes the Oligonucleotide Synthesis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Equipment, Linkers & Adaptor, Probes, Reagents & Consumables, Services, and Synthesized Oligonucleotides.
• Based on Type, market is studied across Custom and Pre-designed.
• Based on Application, market is studied across Diagnostic, Research, and Therapeutic.
• Based on End-User, market is studied across Academic Research Institutes, CROs & CMOs, Diagnostic Laboratories & Hospitals, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and growing focus on drug discovery
    • 5.1.1.2. Rising usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
    • 5.1.1.3. Significant investments in pharmaceutical and biotechnology research
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of oligonucleotides production
  • 5.1.3. Opportunities
    • 5.1.3.1. Improvements and advances in oligonucleotide synthesis
    • 5.1.3.2. Strategic alliances for increasing production of oligonucleotides
  • 5.1.4. Challenges
    • 5.1.4.1. Complications associated with large scale oligonucleotide synthesis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing usage of synthesized oligonucleotides for aiding research and treatment design
  • 5.2.2. End-User: High potential of oligonucleotide synthesis among academic research institutes for developing new scientific techniques
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oligonucleotide Synthesis Market, by Product

• 6.1. Introduction
• 6.2. Equipment
• 6.3. Linkers & Adaptor
• 6.4. Probes
• 6.5. Reagents & Consumables
• 6.6. Services
• 6.7. Synthesized Oligonucleotides

7. Oligonucleotide Synthesis Market, by Type

• 7.1. Introduction
• 7.2. Custom
• 7.3. Pre-designed

8. Oligonucleotide Synthesis Market, by Application

• 8.1. Introduction
• 8.2. Diagnostic
• 8.3. Research
• 8.4. Therapeutic

9. Oligonucleotide Synthesis Market, by End-User

• 9.1. Introduction
• 9.2. Academic Research Institutes
• 9.3. CROs & CMOs
• 9.4. Diagnostic Laboratories & Hospitals
• 9.5. Pharmaceutical & Biotechnology Companies

10. Americas Oligonucleotide Synthesis Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Oligonucleotide Synthesis Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Oligonucleotide Synthesis Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Codexis Introduces Eco Synthesis Platform for Enhanced Oligonucleotide Manufacturing
  • 13.3.2. CordenPharma Enhances Oligonucleotide Production with Strategic Expansion in Colorado
  • 13.3.3. Oligo Factory Launches Advanced Oligonucleotide Production Facility
  • 13.3.4. UK's Innovative Collaboration Aims to Transform Oligonucleotide Production
  • 13.3.5. Agilent Technologies Expands Oligonucleotide Production Capacity
  • 13.3.6. Aurisco and Cytiva Launch China's First Oligo FlexFactory
  • 13.3.7. Wuxi STA Expands with New Oligonucleotide and Peptide Production Facility in China
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Ajinomoto Bio-Pharma Services
• 3. ATDBio Ltd.
• 4. Bio-synthesis Inc.
• 5. Biocomma Ltd.
• 6. Biolegio B.V.
• 7. Biolytic Lab Performance Inc.
• 8. Bioserve India by Reprocell Group
• 9. Bon Opus Biosciences, LLC
• 10. Creative Biogene
• 11. Cusabio Technology LLC
• 12. Danaher Corporation
• 13. Eurofins Genomics LLC
• 14. Eurogentec S.A. by Kaneka Corporation
• 15. GE Healthcare Inc.
• 16. Generi Biotech
• 17. Genscript Corporation
• 18. Hongene Biotech Corp.
• 19. LGC Genomics Limited
• 20. Merck KGaA
• 21. Microsynth AG
• 22. Nitto Denko Avecia Inc.
• 23. Novartis AG
• 24. PerkinElmer, Inc.
• 25. Synbio Technologies
• 26. TAG Copenhagen A/S
• 27. TCI Chemicals (India) Pvt. Ltd.
• 28. Thermo Fisher Scientific Inc.
• 29. TriLink BioTechnologies, Inc.